

Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Ref: FOI-000377

Date: 18/10/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following questions:

Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 7
- Amivantamab
- Atezolizumab Monotherapy 1
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
- Dabrafenib + Trametinib
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 8
- Durvalumab
- Gemcitabine
- Nitedanib + Docetaxel
- Nivolumab
- Osimertinib
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 10
- Paclitaxel
- Pembrolizumab Monotherapy 18
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 8
- Pemetrexed + Platinum (Carboplatin/Cisplatin) 8
- RET Inhibitors (Pralsetinib, Selpercatinib)
- Sotorasib
- Tepotinib
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 6
- Other active systemic anti-cancer therapy 11
- Palliative care only

Q2. Of all the NSCLC patients treated with nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with nivolumab? - N/A

FOI/REF FOI-

Q3. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part. - No active trials

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust